Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation

Clin Transplant. 2006;20 Suppl 17:80-4. doi: 10.1111/j.1399-0012.2006.00605.x.

Abstract

Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.

Publication types

  • Review

MeSH terms

  • Delayed-Action Preparations
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Kidney Transplantation*
  • Liver Transplantation*
  • Tacrolimus / administration & dosage*

Substances

  • Delayed-Action Preparations
  • Immunosuppressive Agents
  • Tacrolimus